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ReseaRch
Mortality due to cancer treatment delay: systematic review and 
meta-analysis
Timothy P Hanna,1,2,3 Will D King,3 Stephane Thibodeau,2 Matthew Jalink,1,2 Gregory A Paulin,2 




To quantify the association of cancer treatment delay 
and mortality for each four week increase in delay to 
inform cancer treatment pathways.
Design
Systematic review and meta-analysis.
Data sOurces
Published studies in Medline from 1 January 2000 to 
10 April 2020.
eligibility criteria fOr selecting stuDies
Curative, neoadjuvant, and adjuvant indications 
for surgery, systemic treatment, or radiotherapy for 
cancers of the bladder, breast, colon, rectum, lung, 
cervix, and head and neck were included. The main 
outcome measure was the hazard ratio for overall 
survival for each four week delay for each indication. 
Delay was measured from diagnosis to first treatment, 
or from the completion of one treatment to the start 
of the next. The primary analysis only included high 
validity studies controlling for major prognostic 
factors. Hazard ratios were assumed to be log linear 
in relation to overall survival and were converted to 
an effect for each four week delay. Pooled effects were 
estimated using DerSimonian and Laird random effect 
models.
results
The review included 34 studies for 17 indications 
(n=1 272 681 patients). No high validity data were 
found for five of the radiotherapy indications or for 
cervical cancer surgery. The association between delay 
and increased mortality was significant (P<0.05) for 13 
of 17 indications. Surgery findings were consistent, 
with a mortality risk for each four week delay of 1.06-
1.08 (eg, colectomy 1.06, 95% confidence interval 
1.01 to 1.12; breast surgery 1.08, 1.03 to 1.13). 
Estimates for systemic treatment varied (hazard ratio 
range 1.01-1.28). Radiotherapy estimates were for 
radical radiotherapy for head and neck cancer (hazard 
ratio 1.09, 95% confidence interval 1.05 to 1.14), 
adjuvant radiotherapy after breast conserving surgery 
(0.98, 0.88 to 1.09), and cervix cancer adjuvant 
radiotherapy (1.23, 1.00 to 1.50). A sensitivity 
analysis of studies that had been excluded because 
of lack of information on comorbidities or functional 
status did not change the findings.
cOnclusiOns
Cancer treatment delay is a problem in health systems 
worldwide. The impact of delay on mortality can now 
be quantified for prioritisation and modelling. Even 
a four week delay of cancer treatment is associated 
with increased mortality across surgical, systemic 
treatment, and radiotherapy indications for seven 
cancers. Policies focused on minimising system level 
delays to cancer treatment initiation could improve 
population level survival outcomes.
Introduction
Delay in the treatment of cancer can have adverse 
consequences on outcome. However, despite its 
foundational importance, we lack standardised 
estimates of the effect of treatment delay on survival 
for most treatment indications. Previous meta-
analyses have found evidence supporting a continuous 
association between delay and mortality1 2 or local 
control.3 A wide variation in reporting of delay 
estimates has limited meta-analysis.4 Understanding 
the impact of delay on mortality and other outcomes 
such as recurrence or financial impact on patients is 
essential to designing cancer care systems, pathways, 
and models of care that deliver affordable and equitable 
outcomes.5
The need for an in-depth understanding of 
the impact of treatment delay on outcomes has 
come sharply into focus during the coronavirus 
2019 (covid-19) pandemic. Many countries have 
experienced deferral of elective cancer surgery and 
radiotherapy, and reductions in the use of systemic 
treatments6 7 because systems have reassigned 
healthcare resources to pandemic preparedness.8 The 
lack of high quality data on the impact of deferred and 
delayed cancer treatment has meant that the impact of 
covid-19 lockdown measures on patterns of care and 
subsequent outcomes has not been robustly quantified. 
More broadly, in non-pandemic times, health systems 
have developed pathways and targets for intervals from 
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WhAt Is AlreAdy knoWn on thIs topIc
Delay in the treatment of cancer can have adverse consequences on outcome
Previous meta-analyses of high validity studies have found evidence supporting 
a continuous relation between delay and mortality or local control
Despite its foundational importance, we lack standardised estimates of the effect 
of treatment delay for most treatment indications
WhAt thIs study Adds
This systematic review considered seven major cancer types (bladder, breast, 
colon, rectum, lung, cervix, and head and neck) and three treatment modalities 
(surgery, systemic treatment, and radiotherapy)
The data consistently show that a four week treatment delay is associated with 
increased mortality; further mortality was reported with longer delays
Policies focused on minimising system level delays in cancer treatment initiation 
could improve population level survival outcomes
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the time of diagnosis to receipt of treatment within 
National Cancer Control Plan frameworks that do not 
have a strong empirical basis.9
Our analysis aims to provide robust evidence to guide 
national policy making, specifically the prioritisation 
and organisation of cancer services, by investigating 
the association between delays in receipt of cancer 
treatment and mortality. We considered seven common 
cancers and provide estimates on the impact of delay 
across all three curative modalities: surgery, systemic 
treatment, and radiotherapy delivered in the radical, 
neoadjuvant, and adjuvant setting.
Methods
Population
We investigated seven cancers that together represent 
44% of all incident cancers globally10: five common 
cancers (bladder, breast, colon, rectum, lung); cervical 
cancer, given its global importance as the fourth 
most common cancer diagnosis among women; and 
head and neck cancer (a major burden in middle 
income settings), for which there is an established 
association between delay and mortality.10 We selected 
these cancers by balancing representativeness with 
comprehensiveness. We also considered rectal and 
colon cancer separately given that radiotherapy is 
an integral part of treatment for rectal cancer but 
not colon cancer. Because of the generally indolent 
nature of prostate cancer (particularly for low and 
intermediate risk disease) compared with other 
cancers, and a preliminary review of the delay 
literature, this cancer was excluded because delays 
of the magnitude considered in our analysis were 
probably not associated with increased mortality.
exposure
Treatment delay was defined as time from diagnosis 
to treatment for the first treatment (definitive surgery 
or radiation), and from time of surgery to treatment 
for adjuvant indications (chemotherapy or radiation 
after surgery). For neoadjuvant treatments (those 
delivered before primary curative therapy, eg, surgery), 
delay was defined as the time from diagnosis to the 
start of neoadjuvant treatment, or from the end of 
neoadjuvant treatment to time of surgery. Delay of 
curative treatments was investigated (surgery, systemic 
treatment, and radiotherapy).
Outcome
A hazard ratio for overall survival was estimated for 
each four week increase in delay. The hazard ratio 
represents the risk of death from any cause for patients 
experiencing the observed treatment delay compared 
with those treated without the delay.
systematic review
We undertook a systematic review to identify high 
validity studies quantifying the impact of treatment 
delay on mortality. The PRISMA (preferred reporting 
items for systematic reviews and meta-analyses) 
guidelines were followed.11 We used Ovid Medline to 
carry out the search (appendix 1). To fully assess the 
validity of included studies, we did not search the 
literature for studies in abstract form only. Studies were 
limited to English language publications, from 2000 to 
present, and those reporting specifically on treatment 
delay and survival for the seven cancers being analysed. 
The year 2000 was selected to be comprehensive, while 
limiting reports to those reflective of contemporary 
practice as much as possible. We included studies if 
they specifically reported on the impact of delay for a 
well defined cancer indication. Studies that reported 
predominantly on patients receiving neoadjuvant 
treatments were excluded when evaluating the impact 
of treatment delay from diagnosis to definitive surgery. 
Studies that investigated the therapeutic benefit of 
intentional moderate delay between completion of 
neoadjuvant therapy for rectal cancer and surgery 
were excluded given potential confounding by 
indication. We did not exclude any studies based on 
design, except that the study needed to quantify the 
hazard ratio for overall survival because of treatment 
delay. The search was run on 10 April 2020, except 
for the bladder cancer search which was performed 
on 22 April 2020. Two reviewers screened abstracts 
by using Covidence systematic review software 
(Veritas Health Innovation, Melbourne, Australia). 
Searches of reference lists and Google were also 
performed.
We reviewed studies for evidence of control for major 
prognostic factors to assess risk of bias. The criteria 
used were consistent with those used by our group 
in other systematic reviews of delay and outcomes.1-3 
Visual Abstract Mortality due to cancer treatment delay
Quantification to support prioritisation and modelling
Policies minimising system level delays to starting treatment could 
potentially improve survival after cancer diagnosis
Summary
Study design Systematic review and meta-analysis
Patients of all ages with 
seven major cancer types
34 studies on 17 cancer treatment indications
1 272 681 participants treated
Data sources
© 2020 BMJ Publishing group Ltd.http://bit.ly/BMJctd
Mortality increases 
as delay increases
Breast cancer surgery 
delay for  women
(baseline % mortality)
Evidence quality
Only high validity 
studies accounting 
for major prognostic 
factors were included
Outcomes
Mortality for each four 
week increase in delay
Surgery Adjuvant treatment*
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Comparison Exposure and outcome
Patient survival according to wait time for treatment 
including surgery, systemic treatment, or radiotherapy
* Adjuvant systemic treatment, apart from head 
and neck cancer, which was adjuvant radiotherapy
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Firstly we asked “was the distribution of the relevant 
prognostic factors adequately described in the 
groups of patients which were compared?” Relevant 
prognostic factors for all studies were considered to 
be age, stage, treatment description, and comorbidity 
or functional status. If no, the study was classified as 
not of high validity. If yes, we proceeded to the next 
question “Were the comparison groups balanced with 
respect to the relevant prognostic factors?” If yes, the 
study was classified as high validity. We qualitatively 
assessed the magnitude of observed differences, 
and the P value was considered when interpreting 
these differences. If no, we asked “Were the reported 
results appropriately adjusted for any differences in 
the relevant prognostic factors?” If yes, the study was 
classified as high validity; if no, the study was classified 
as not high validity. Only studies meeting these criteria 
were included for subsequent meta-analysis.
For some definitive indications (colon cancer, lung 
cancer, cervical cancer), it was possible that observed 
associations between treatment delay and risk of death 
were attenuated because patients with poorer outcomes 
might present more quickly with symptomatic disease 
through emergency or urgent referral pathways (often 
referred to as the waiting time paradox).12 To qualify as 
high validity, such studies were required to have also 
performed an analysis or subanalysis to investigate 
the impact of this factor in the observed associations. 
Similar to Neal and colleagues, this was defined as an 
analysis or subanalysis of patients clearly including or 
excluding patients with short diagnosis to treatment 
interval (eg, less than four weeks) or poor outcomes 
(eg, death within four to eight weeks of diagnosis).12
converting hazard ratios to four week delay 
estimates
There was heterogeneous reporting of results, with 
time intervals reported as dichotomous, ordinal 
categories or as continuous variables. Results were 
converted to a common unit—hazard ratio for each four 
week delay with the assumption of a log linear relation 
across waiting times based on the findings of other 
meta-analyses.1-3 A log linear relation predicts, for 
example, that patients waiting eight weeks rather than 
four weeks have a doubling in their risk of death. A unit 
of four weeks was chosen based on the magnitude of 
waiting times reported in the literature. We emphasise 
that the hazard ratio calculated in this study might be 
converted to shorter (eg, each week or each day) or 
longer units. Appendix 2 provides further information 
on the conversion of hazard ratios to each four week 
delay estimates or other units, and compares the log 
linear model to the linear model.
Meta-analysis
We obtained the summary hazard ratio estimate by 
pooling hazard ratios for each four week delay with 
inverse variance weighting in DerSimonian and 
Laird random effect models. Heterogeneity between 
studies was evaluated using the I2 test. We performed 
the statistical analysis using the R package metafor 
(R Foundation for Statistical Computing, Vienna, 
Austria). We considered a two tailed P value less than 
0.05 to be statistically significant. Publication bias was 
not tested given the small number of studies identified 
for each indication.
sensitivity analysis
We undertook a post hoc sensitivity analysis to evaluate 
the impact of the stringent validity criteria on findings. 
Studies that had been excluded in the main analysis 
because of a lack of information on comorbidities 
or functional status were included in this analysis 
because other factors such as increasing age could be 
proxies for these.
Patient and public involvement
The research was informed by patient groups and 
cancer charities that were concerned about the impact 
of cancer treatment deferral and delays during the 
covid-19 pandemic.
results
Our search identified 2543 articles for review (fig 1).11 
After we added records identified through additional 
sources, and removed duplicates, 2843 records 
were screened. The primary reason for exclusion 
at the screening stage was lack of relevance to the 
study question. We obtained 275 articles to assess 
for eligibility. Of these, 241 were excluded, most 
commonly because they were not high validity studies 
(n=100), they included the wrong patient population 
(n=36), or the wrong study design (n=26). This left 34 
studies with unique populations for inclusion (fig 1, 
table 1, table 2).13-46 These studies included 1 272 681 
patients, with a sample size ranging from 174 to 420 792 
(appendix 3). Twenty eight studies were population or 
registry based, and six were institutional reports. All 
studies were retrospective observational comparisons. 
Abstracted data on delay were dichotomous in eight, 
continuous in nine, and categorical in 17 studies. 
Waiting time data generally covered from three to four 
weeks, to 16 weeks (appendix 3). Appendix 3 presents 
the association between treatment delay and survival 
for individual studies. In addition to adjustments for 
age, stage, and comorbidity or functional status, 91% 
of studies accounted for one or more socioeconomic 
variables in their analysis, 82% accounted for 
insurance status, 65% for year of treatment or year of 
diagnosis, and 88% for institutional or geographical 
factors (appendix 4). We did not find any high validity 
data for five radiotherapy indications or cervical cancer 
surgery (table 1, table 2).
Figure 2, figure 3, figure 4 show summary results 
for all indications, with pooled estimates displayed 
for treatment site combinations where more than one 
high validity study exists. The random effects models 
showed a consistent association of surgical delay 
with increased mortality, with all indications showing 
a hazard ratio for each four week delay of between 
1.06 and 1.08 (6-8% increased chance of death for 
each four week delay in treatment). For example, 
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for head and neck surgery the hazard ratio was 1.06 
(95% confidence interval 1.04 to 1.08) and for breast 
partial or complete mastectomy the hazard ratio was 
1.08 (1.03 to 1.13). The results for lung surgery were 
consistent with other sites, though not statistically 
significant (1.06, 0.93 to 1.19).
Adjuvant and neoadjuvant systemic treatment 
indications varied more widely in effect (hazard ratio 
range 1.01-1.28). We observed significant associations 
for bladder neoadjuvant systemic treatment (hazard 
ratio 1.24, 95% confidence interval 1.03 to 1.50), 
breast adjuvant (1.09, 1.07 to 1.11) and neoadjuvant 
systemic treatment (1.28, 1.05 to 1.56), and colon and 
rectal adjuvant chemotherapy (1.13, 1.09 to 1.17). 
Associations were non-significant for non-small cell 
lung cancer adjuvant chemotherapy (1.01, 0.99 to 
1.04) and bladder adjuvant chemotherapy (1.04, 0.98 
to 1.11).
High validity data on curative radiotherapy were 
limited, but supported a mortality impact of delay 
for head and neck cancer (eg, radical radiotherapy: 
1.09, 1.05 to 1.14) and for cervical cancer adjuvant 
radiotherapy (1.23, 1.00 to 1.50; P=0.045). We found 
no significant effect for the single high validity study 
of adjuvant radiotherapy after breast conserving 
surgery (0.98, 0.88 to 1.09). No high validity studies 
were found for delay between diagnosis and start of 
neoadjuvant therapy for rectal cancer or for four other 
curative radiotherapy indications (table 2).
sensitivity analysis
To evaluate the impact of our validity criteria on study 
findings, we undertook a sensitivity analysis and 
included studies that could be considered of border- 
line validity. For this analysis, we included 12 studies 
that were excluded in the primary analysis solely 
because of the lack of reporting or adjustment for 
comorbidity or functional status. We found little 
change in our estimates, except for breast cancer 
neoadjuvant syste mic treatment (appendix 5).
discussion
Principal findings
This analysis reports the impact of delay in curative 
treatment on the risk of death across the seven major 
tumour types: bladder, breast, colon, rectum, lung, 
cervix, and head and neck, and across all three major 
treatment modalities (surgery, systemic treatment, and 
radiotherapy). Across all three modalities, we found 
that a treatment delay of four weeks is associated 
Additional records identified through other sources
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134
fig 1 | PrisMa (preferred reporting items for systematic reviews and meta-analyses) 2009 flow diagram for systematic 
review of treatment delay and survival for curative surgery, systemic treatment, and radiotherapy for bladder, breast, 
colon, rectum, lung, cervix, and head and neck cancer. Hr=hazard ratio
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with an increase in the risk of death. For surgery, this 
is a 6-8% increase in the risk of death for every four 
week delay. This impact is even more marked for some 
radiotherapy and systemic indications, with a 9% and 
13% increased risk of death for definitive head and 
neck radiotherapy and adjuvant systemic treatment for 
colorectal cancer, respectively. The one high validity 
study for breast cancer adjuvant radiotherapy did not 
show an effect, although a clear effect of delay on local 
control has been described (hazard ratio for each month 
of delay 1.08, 95% confidence interval 1.02 to 1.14); 
longer delays (eg, >20 weeks) have been associated 
with worse breast cancer specific survival.47 48
Policy implications and comparison to other studies
Our analysis builds on the foundations of Mackillop 
and colleagues, who investigated the mortality impact 
per one month delay for radiotherapy indications 
(eg, head and neck, breast) and similarly for systemic 
treatment (adjuvant colon, breast).1-3 47 Our study 
provides a strong empirical basis for estimating the 
mortality impact of system level delays for different 
treatment modalities and cancers.
Delays of up to eight weeks and 12 weeks further 
increase the risk of death. For example, an eight week 
delay in breast cancer surgery would increase the risk 
of death by 17% (=1.088weeks/4weeks) and a 12 week delay 
would increase the risk by 26% (=1.0812weeks/4weeks). 
Such figures translate into significant population level 
excess mortality. A surgical delay of 12 weeks for all 
patients with breast cancer for a year (eg, during 
covid-19 lockdown and recovery) would lead to 1400 
excess deaths in the United Kingdom, 6100 in the 
United States, 700 in Canada, and 500 in Australia, 
assuming surgery is the first treatment in 83%, and 
mortality without delay is 12%.10 16 49 These results 
are sobering and suggest that the survival gained by 
minimising the time to initiation of treatment is of 
similar (and perhaps greater) magnitude of benefit 
as that seen with some novel therapeutic agents.50 
Furthermore, our results do not consider the impact 
of treatment delay on local control rates, functional 
outcomes (eg, continence, swallowing), complications 
from more extensive treatments because of progression 
during delays, quality of life,51 or the greater economic 
burden because of higher direct care costs and 
productivity losses because of premature mortality and 
morbidity.52 Therefore, the impact of treatment delay is 
probably far greater for patients and society than that 
reflected in our results.
table 1 | summary of characteristics for studies investigating surgical treatment
indication: 
surgery source study design Dataset (dates) Median age (years) stage Other study details
Bladder Chu 201913 Retrospective observational 
comparison
SEER Medicare database 
(2004-2012)
75.2 (mean) II —
Gore 200914 Retrospective observational 
comparison
SEER Medicare database 
(1992-2001)
≤12 weeks=73.8, >12 
weeks=73.6 (mean)
II —
Kulkarni 200915 Retrospective observational 
comparison
Ontario Cancer Registry 
(1992-2004)
≤90 days 67.4,  
>90 days 69.2 (mean)
Tx, T0, Ta, Tis, T1-T4 —
Breast Bleicher 201616 Retrospective observational 
comparison




75.2 (mean),  
60.3 (mean)
I-III, I-III Both cohorts were included 
in meta-analysis as overlap 
was limited owing to years 
considered in two cohorts, 
wider geographical population 
coverage of NCDB with ≥18 
years represented (SEER was 
≥66 years)
Eaglehouse 201917 Retrospective observational 
comparison
CCR, MDR databases 
(1998-2010)
54.5 (mean) I-III —
Polverini 201618 Retrospective observational 
comparison
NCDB (2004-2012) 59.4 (mean) I-III —
Shin 201319 Retrospective observational 
comparison
KCCR database (2006) 49.3 (mean) Local and regional 
(SEER)
—
Mateo 202020 Retrospective observational 
comparison
NCDB (2010-2014) NR I-III —




71 (range 18-99) I-IV (pathological) —
Flemming 201722 Retrospective observational 
comparison
OCR, CIHI DAD, OHIP  
databases (2002-2008)
71 (IQR 62-78) I-IV (pathological) —
NSCLC Kanarek 201423 Retrospective observational 
comparison
Institutional US  
(2003-2009)
61% ≥65 1A, 1B/2A, 2B —
Samson 201524 Retrospective observational 
comparison
NCDB (1998-2010) <8 weeks: 67.63 (±10.1), 
≥8 weeks: 68.73 (±9.8) 
(mean (±SD))
I (clinical) —
Cervix No high validity data found
Head and 
neck
Murphy 201625 Retrospective observational 
comparison
NCDB (2003-2005) NR I-IVB Oral tongue, oropharynx,  
larynx, hypopharynx
Liao 201726 Retrospective observational 
comparison
Taiwanese Cancer Registry 
database (2004-2010)
52.8 (mean) I-IVB (clinical) Oral cavity
CCR=Department of Defence Central Cancer Registry; CIHI DAD=Canadian Institute for Health Information Discharge Abstract Database; IQR=interquartile range; KCCR=Korean Central Cancer 
Registry; MDR=Military Health System Data Repository; NCDB=National Cancer Database (US); NR=not reported; NSCLC=non-small cell lung cancer; OCR=Ontario Cancer Registry; OHIP=Ontario 
Health Insurance Plan; SEER=Surveillance, Epidemiology, and End Results.
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table 2 | summary of characteristics for studies investigating systemic treatment and radiotherapy




Chu 201913 Retrospective observational 
comparison
SEER Medicare database 
(2004-2012)
72.9 (mean) II Same study as Chu 
201913 bladder surgery
Adjuvant chemotherapy,  
bladder
Corbett 201927 Retrospective observational 
comparison
NCDB (2006-2013) NR pT3-T4 or pN+ —
Booth 201428 Retrospective observational 
comparison






Sanford 201629 Retrospective observational 
comparison
Research database at 
University of Texas  
(1995-2007)
50 (range 24-83) I-III (clinical) Time from end of  
neoadjuvant  
chemotherapy to surgery
Adjuvant chemotherapy,  
breast
Gagliato 201430 Retrospective observational 
comparison
MD Anderson Cancer 
Center institutional  
database. (1997-2011)
50 (range 19-85) I-III —
Mateo 202020 Retrospective observational 
comparison
NCDB (2010-2014) NR I-III —
Hershman 200631 Retrospective observational 
comparison
SEER Medicare database 
(1992-1999)
NR I-II —
Adjuvant chemotherapy,  
colon, rectum
Hershman 200632 Retrospective observational 
comparison
SEER Medicare database 
(1992-1999)
NR III Colon —
Cheung 200933 Retrospective observational 
comparison




II- III Rectal —
Bayraktar 201134 Retrospective observational 
comparison
Jackson Memorial Hospital 




55.7±1.1 for ≤60 
days and 56.9±1.8 
for >60 days 
(mean±SE)
II-III Colon —
Lima 201135 Retrospective observational 
comparison
Alberta Cancer Registry, 
ambulatory care  
classification system, 
discharge abstract  
database (2000-2005)
NR III Colon —
Becerra 201736 Retrospective observational 
comparison
New York State Registry, 
SPARCS (2004-2009)
NR III Colon —
Turner 201837 Retrospective observational 
comparison
NCDB (2006-2014) NR III Colon —
Xu 201438 Retrospective observational 
comparison





Massarweh 201539 Retrospective observational 
comparison
NCDB (2003-2010) 60.8 (±11.6)  
(mean (±SD))
III Colon —
Adjuvant chemotherapy,  
NSCLC
Booth 201340 Retrospective observational 
comparison





Salazar 201741 Retrospective observational 
comparison






No high validity  
data found






Random population based 
sample of five regions of 





No high validity  
data found
NSCLC, stage III  
chemoradiation
No high validity  
data found
SCLC, limited stage  
chemoradiation




Jhawar 201743 Retrospective observational 
comparison
NCDB (2004-2013) 46 (IQR 38-56) IB1-IIIB No stratified wait  




No high validity  
data found
Radical chemoradiation,  
head and neck
Sharma 201644 Retrospective observational 
comparison








Harris 201845 Retrospective observational 
comparison





subsite and outcome 
observed
Radical (chemo)radiation,  
nasopharyngeal carcinoma
Chen 201646 Retrospective observational 
comparison
Sun Yat-Sen University 
Cancer Center, institutional 
series (2009-2012)




99.6% World Health  
Organization histology 
type II/III, treated with IMRT
IMRT=intensity modulated radiation therapy; IQR=interquartile range; NCDB=National Cancer Database (US); NR=not reported; NSCLC=non-small cell lung cancer; OCR=Ontario Cancer Registry; 
SCLC=small cell lung cancer; SD=standard deviation; SE=standard error; SEER=Surveillance, Epidemiology, and End Results; SPARCS=Statewide Planning and Research Cooperative System.
*Delay studies primarily investigating therapeutic benefit of usually short delay between completion of neoadjuvant treatment and surgery for rectal cancer are excepted. No high validity studies 
investigating time from diagnosis to start of neoadjuvant therapy were found for rectal cancer.
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Treatment delays could be due to patient factors 
(eg, need for cardiac workup, postoperative wound 
infection), disease factors (eg, need for additional 
imaging investigations), or system factors (eg, waiting 
for an operating room date, a central line insertion, 
or a specialist consultation). The main purpose of 
this discussion is to highlight the need to minimise 
system level delays. We strongly emphasise that 
patients should not start surgery, systemic treatment, 
or radiotherapy until they are medically fit to do so, 
and have completed appropriate investigations. We 
also acknowledge that for rectal cancer, for instance, 
an increasing body of evidence shows that deferral of 
surgery after radiotherapy might not confer a survival 
disadvantage for those having a complete response.53
A major finding from our study is the paucity of high 
quality data for several tumour specific indications 
for radiotherapy, including chemoradiation for non-
small cell lung cancer and definitive cervical cancer 
treatment. Two high validity studies providing delay 
estimates across multiple treatment modalities for 
these tumour types suggest an impact of delay in 
treatment initiation in these settings (cervical cancer 
mortality for each four week delay: hazard ratio 1.04, 
95% confidence interval 1.02 to 1.0754; stage III non-
small cell cancer: 1.03, 1.01 to 1.06).55 While the 
negative impact of treatment interruptions on survival 
outcomes is well documented for these tumours,56-58 
evidence is insufficient about the exact impact of a 
delay in starting treatment, which given its importance, 
should be an urgent research priority.
The study results are timely in light of the current 
covid-19 pandemic. Internationally, some countries 
have released national guidance on prioritisation of 
surgical treatments for cancer, which do not appear to 
be supported by the results of this study. For example, 
at the beginning of the pandemic the UK NHS59 created 
a short term surgical prioritisation algorithm. Several 
indications were considered safe to be delayed by 10-12 
weeks with no predicted impact on outcome, including 
all colorectal surgery. Therefore, our results can help 
to directly inform policy—we found that increasing 
the wait to surgery from six weeks to 12 weeks would 
increase the risk of death in this setting by 9%.
We note that a delay of less than four weeks should not 
be justified as safe based on our findings. For example, 
our results suggest a 4% increased risk of death for a two 
week delay for breast cancer surgery (1.082weeks/4weeks; 
Bladder
  Chu 2019
  Gore 2009
  Kulkarni 2009
RE model: Q=4.26; df=2, P=0.12; I2=53.0%
Breast
  Mateo 2020
  Eaglehouse 2019
  Bleicher (NCBD) 2016
  Bleicher (SEER) 2016
  Polverini 2016
  Shin 2013
RE model: Q=84.79; df=5, P=0.00; I2=94.1%
Colon
  Bagaria 2019
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fig 2 | forest plot and pooled hazard ratios for association of each four week delay in surgery and overall survival by 
cancer site. small purple diamonds represent the hazard ratio for each study and whiskers represent 95% confidence 
interval. large purple diamonds represent summary effect estimates with the centre being the estimate and the ends 
representing 95% confidence intervals. nsclc=non-small cell lung cancer  on 1 F
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appendix 2). Taken as a whole, these results suggest 
there is an urgent need to reconsider how we organise 
our cancer services. The prevailing paradigm has been 
around access to new treatments to improve outcomes, 
but from a system level, gains in survival might be 
achieved by prioritising efforts to minimise the time 
from cancer diagnosis to initiation of treatment from 
weeks to days. We acknowledge that treatment delays 
are multifactorial in cause and that patients should not 
start treatment before they are medically fit to do so, 
and have had completed all appropriate evaluations, 
however these data strongly support efforts to minimise 
system level delays. For example, national quality 
indicators around cancer waiting times from diagnosis 
to treatment are widely used across different health 
systems. In the UK NHS, current targets for the initiation 
of primary definitive treatment have been set at 31 days 
from the decision to treat date; this does not include the 
lag between receiving a diagnosis and having a surgical 
or radiation oncology consultation for treatment.9  60 
At a population level, differences in lead times to 
treatment of even two or three weeks could be a factor 
in why survival outcomes differ across health systems 
and needs further investigation. However, these delays 
need to be balanced with the necessity to be medically 
fit for treatment. Additionally, potential opportunities 
for second opinions could result in more effective or 
appropriate care, especially where variation in practice 
or outcomes exist across providers.
Options for decreasing delay after diagnosis include 
increasing specialist workforce capacity through 
training initiatives or overcoming these challenges 
through technological developments. For example, 
automated treatment contouring and planning is 
increasingly standardised and reduces the radio- 
therapy preparation time to hours rather than 
days.61 Satellite centres might improve capacity for 
treating patients, as can reconfiguration of existing 
infrastructure to high volume super specialised 
services, or single entry models and team based care.62 
Innovations in surgical technique could also minimise 
morbidity and reduce time to adjuvant therapy.63 64
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fig 3 | forest plot and pooled hazard ratios for association of each four week delay in adjuvant and neoadjuvant 
systemic treatment and overall survival by cancer site. small purple diamonds represent the hazard ratio for each 
study and whiskers represent 95% confidence interval. large purple diamonds represent summary effect estimate 
with the centre being the estimate and the ends representing 95% confidence intervals. nsclc=non-small cell lung 
cancer
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strengths and limitations of this study
Our study provides evidence on the association of 
treatment delay and mortality, covering seven cancer 
types and three treatment modalities. Our study 
was based on observational data, and we therefore 
restricted our sample to high validity studies given 
the biases inherent to this study design. Our approach 
provides high level evidence on system delay because 
randomised trials in this context are not appropriate or 
feasible.
The most fundamental limitation of our study is 
the risk of residual confounding. Patients with longer 
treatment delays could be destined to have inferior 
outcomes for reasons of comorbidity, treatment 
morbidity, or performance status. In evaluating the 
validity of our findings, we note the coherence of 
overall mortality and cancer specific endpoints (local 
control, cancer specific survival, disease-free survival) 
for all past meta-analyses of high validity studies.1-3 47 
We also note major detrimental effects of prolonged 
waiting times on cancer specific survival outcomes in 
13 of 15 studies included in our meta-analysis that 
reported cancer survival outcomes alongside overall 
survival.14 16 22 28 29-36 38 39 46 These studies span seven 
treatment indications. Factors associated with medical 
status such as elements of socioeconomic status or 
insurance status might also be confounding factors; 
we found that 91% and 82% of identified studies 
accounted for these, respectively, though this does 
not completely rule out the possibility of residual 
confounding. Twenty five of 34 identified studies were 
from the USA, though no significant heterogeneity was 
detected compared with other countries.
Our findings cannot be directly applied to other 
cancer specific treatment indications, or to subgroups 
or single patients with treatment indications consi-
dered here. For example, limited evidence suggests 
that the impact of delay can vary according to stage, 
often with consistently greater mortality impact with 
earlier stage disease.16-18 25 55 Additionally, our results 
can only be applied to the range of delay considered in 
the studies we evaluated. Given evidence derived from 
cancers representing almost half of all patients, the 
precautionary principle (acting to avoid or diminish 
harm in the face of scientific uncertainty) should be 
used when determining acceptable waiting times for 
treatment where data are limited.8 Too few studies 
were found for most indications to perform a risk of 
publication bias assessment with funnel plots. For 
previous meta-analyses where enough studies existed 
to do so, findings were not explained by publication 
bias.1 2
We acknowledge that the assumption of a log linear 
relation between waiting time and mortality could be 
an oversimplification. This assumption was required to 
estimate per unit time mortality impact of delay from 
studies that use a variety of wait time representations. 
However, there is support for this assumption in the 
primary studies we used. A continuous exposure 
from nine primary studies assumed (log) linearity. Six 
studies undertook cubic spline analysis and the results 
are compatible with log linear effects with the range 
of wait times considered here (four weeks to 16 
weeks).15 19 21 26 41 45 Moreover, the previous meta-
analyses by Biagi and colleagues and Raphael and 
colleagues suggest a reasonable fit of a log linear 
relation to delay.1 2 If a linear relation with delay exists 
(rather than log linear), the degree of difference in the 
two models is expected to be sufficiently small to allow 
use of a log linear model for the specific purposes of 
modelling the impact of delay on mortality between 
four and 16 weeks (appendix 2). We emphasise that 
assuming log linearity outside of the range of wait 
times used in this analysis is inappropriate. Our 
findings should also not be used to evaluate whether 
there is a minimal safe delay, or to estimate the impact 
of delay beyond 16 weeks.
Our results reflect the impact of delay on large and 
expectedly heterogeneous populations with varying 
risks of recurrence. Therefore, these estimates are 
best used at a policy and planning level for modelling, 
rather than for individual risk prediction. We also 
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fig 4 | forest plot of hazard ratios for association of each four week delay in radical and adjuvant radiotherapy and 
overall survival by cancer site. Purple diamonds represent the hazard ratio for each study and whiskers represent 95% 
confidence interval
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emphasise that few studies considered the impact 
of immortal time bias on delay; this could be done 
through a landmark analysis for survival. Patients 
that survived a longer wait might have less aggressive 
tumours, biasing the delay effect towards the null. Our 
findings could therefore underestimate the impact of 
delay on mortality.
conclusions
A four week delay in treatment is associated with an 
increase in mortality across all common forms of 
cancer treatment, with longer delays being increa-
singly detrimental. In light of these results, policies 
focused on minimising system level delays in cancer 
treatment initiation could improve population level 
survival outcomes.
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